FDA Accepts Priority Review for Linvoseltamab to Treat Adult

Currently, the safety and efficacy of linvoseltamab in adult patients with relapsed or refractory multiple myeloma is being compared to elotuzumab, pomalidomide, and dexamethasone in a phase 3 clinical trial.

Related Keywords

Jo Panuwat , Regeneron Pharmaceuticals , Refractory Multiple Myeloma Accepted For , Acceptance For Treatment , Refractory Multiple , Learn How Well Linvoseltamab Works Compared , Adult Participants With , Refractory Multiple Myeloma ,